Questions and Answers
What percentage of all human cancers does MUO account for?
What is the average age at diagnosis of MUO?
What is the median overall survival (OS) of patients with MUO?
What is the most frequently used imaging modality in the management of patients with MUO?
Signup and view all the answers
What is included in the diagnostic approach of MUO?
Signup and view all the answers
What is the primary characteristic of MUO?
Signup and view all the answers
What is the purpose of PET/CT scan in MUO?
Signup and view all the answers
What is the prognosis of patients with MUO?
Signup and view all the answers
What is the histopathological marker for lymphoma?
Signup and view all the answers
What is the treatment approach for a woman with papillary adenocarcinoma of the peritoneal cavity?
Signup and view all the answers
What is the molecular analysis concept for identifying tumor type?
Signup and view all the answers
What is the indication for adjuvant radiation therapy after lymph node dissection?
Signup and view all the answers
What is the histopathological marker for melanoma?
Signup and view all the answers
What is the treatment approach for a man with bone metastasis from adenocarcinoma with elevated PSA?
Signup and view all the answers
What is the principle of radiation therapy for symptomatic patients?
Signup and view all the answers
What is the histopathological marker for carcinoma?
Signup and view all the answers
Study Notes
Definition and Epidemiology
- MUO (Metastatic Unknown Origin) is a clinical disorder where a patient presents with histologically confirmed metastatic cancer, but standard diagnostic investigations fail to identify the primary site.
- Accounts for 2-9% of all human cancers.
- Considered to be the 7th-8th most frequent malignant tumor.
Clinical Characteristics at Presentation
- Average age at diagnosis of 60 to 75 years.
- Heterogeneous tumors with a wide variety of clinical presentations.
- Absence of the primary, early dissemination, aggressiveness, and unpredictability of metastatic pattern.
- About 80% of patients with MUO have a poor prognosis and median overall survival (OS) of 3 to 10 months.
Major Sites of MUO at Initial Presentation
- Lung metastasis
- Liver metastasis
- Other sites not mentioned
Diagnostic Approach
- Complete history taking and detailed review of past biopsies or malignancies.
- Physical examination including breast, genitourinary, pelvic, and rectal examinations.
- Routine laboratory tests (e.g., complete blood count, electrolytes, liver function tests, creatinine, calcium).
- Occult blood stool testing and tumor markers (e.g., CA15-3, PSA).
- Imaging:
- Computerized tomography (CT) is the most frequently used imaging modality.
- Magnetic resonance imaging (MRI).
- Breast Ultrasound and MAMOGRAPHY.
- Positron emission tomography (PET) scan and a computed tomography (CT) (PET/CT) for radical therapy planning.
- Histopathology:
- Carcinoma (adenocarcinoma, squamous carcinoma): CK (cytokeratin).
- Lymphoma: LCA (LEUCOCYTE COMMON ANTIGEN).
- Melanoma: S100, HMB45.
- Sarcoma: VIMENTINE, S100.
- Molecular analysis: Neoplasm retains gene expression profile based on cellular origin.
- Endoscopy: Symptoms-guided investigational approach.
Treatment
Favorable Prognosis
- Isolated inguinal adenopathy (SCC): Local excision +/- radiotherapy.
- Woman with adenocarcinoma involving axillary lymph node: Managed as breast cancer.
- Woman with papillary adenocarcinoma of peritoneal cavity: Managed as ovarian cancer.
- Adenocarcinoma with colon profile: Managed as colon cancer.
- Men with bone metastasis from adenocarcinoma with elevated PSA: Managed as prostate cancer.
Unfavorable Prognosis
- Male gender, older age (≥65 years), multiple comorbidities: Treated with empirical chemotherapy ± radiotherapy.
- Metastases involving multiple organs (e.g., liver, lung, bone): Treated with empirical chemotherapy ± radiotherapy.
- Peritoneal metastases; multiple cerebral metastases; non-papillary malignant ascites (adenocarcinoma): Treated with empirical chemotherapy ± radiotherapy.
Principles of Radiation Therapy
- Consider adjuvant radiation therapy after lymph node dissection (if the disease is limited to a single nodal site).
- Consider palliative radiotherapy for symptomatic patients with uncontrolled pain, impending pathologic fracture, or impending cord compression.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Identify tumors based on histopathology, molecular analysis, and endoscopy. Learn about carcinoma, lymphoma, melanoma, and sarcoma markers and gene expression profiles.